Finally New Tools Are Available To Combat Drug Resistant Tuberculosis, But How Do We Make Them Work? Models To Determine Effective Implementation Strategies In Australia And Our Region
Funder
National Health and Medical Research Council
Funding Amount
$1,562,250.00
Summary
The risk of drug resistance in tuberculosis (MDR TB) is thwarting control efforts and must be addressed. Potential strategies being considered are; treating MDR TB in the latent phase, using new short-course treatment for active TB and using new vaccines. My work develops simulation models to test strategies before they are implemented, to maximise impact and avoid costly or low-impact interventions. I will examine strategies in Australia and in high burden countries in Australia’s region.
Addressing Evidence Gaps And Developing A Novel Treatment To Reduce The Burden Of Post-traumatic Knee Osteoarthritis
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Arthritis caused by knee injury has a devastating personal and economic impact. Research is needed to develop strategies to prevent arthritis and improve outcomes for people living with arthritis. This research will improve treatment of knee injury to reduce arthritis risk, understand why some people are more likely to get knee arthritis, and develop a new treatment to improve outcomes for people living with knee arthritis. A clinical trial will determine if this treatment achieves this aim.
Improving Outcomes For Cancer Patients By Targeting The Epigenome
Funder
National Health and Medical Research Council
Funding Amount
$2,258,892.00
Summary
The most commonly mutated proteins in cancer involve so called epigenetic regulators, a class of proteins that regulate access to our DNA to control gene expression, DNA repair and replication. We and others have recently developed a variety of drugs to help inhibit the aberrant activity of these epigenetic proteins. My research will focus on ways to improve the efficacy of these existing drugs and find new epigenetic therapies to improve the survival of patients with a broad range of cancers.
Investigating Post-transcriptional Gene Regulation In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
In this program, I will enhance our understanding of cancer gene regulation and provide novel avenues for the treatment of aggressive tumours. Using own data and that from collaborators, I will determine patterns of gene regulation in blood cancers and identify markers that predict disease outcome. I aim to understand how gene regulation can transform healthy cells into tumour cells and whether personalised treatment can kill tumour cells more effectively and prevent relapse and metastasis.
Teaching An Old Brain New Tricks: Optimising Cognitive Training Through Neuroplasticity
Funder
National Health and Medical Research Council
Funding Amount
$1,562,250.00
Summary
People with early dementia have the most to gain from brain training programs aimed at delaying deterioration. Yet, its power is under-realised, with improvements not generalising to everyday living. This research program will harness the power of neuroplasticity to optimise brain training so that the effects transfer to everyday life. The knowledge gained will transform the way that we design and deliver brain training programs and revolutionise our understanding of why and how people respond.
Developing Interpretable Machine Learning Models For Clinical Imaging And Single-cell Genomics
Funder
National Health and Medical Research Council
Funding Amount
$1,312,250.00
Summary
Machine learning methods will be vital to make best use of the deluge of data generated by high-throughput technologies in biomedical science. To get the most out of these models, however, we need to be able to unpack the 'black box'. I will use curated clinical and public research data to benchmark and develop interpretable deep learning models and software tools. These models will be used for breast cancer screening programs and for analysis of complex, large-scale single-cell genomics data.
Targeting Iron Piracy From Host Proteins By Neisseria And Haemophilus Spp. For The Development Of Novel Antimicrobials
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
The bacteria that cause the sexually transmitted infection gonorrhoea and meningococcal disease are a serious health concern. In order to cause disease, these bacteria must obtain the nutrient iron from our bodies. This proposed research will use cutting edge technologies to understand on a molecular level how these bacteria obtain iron during infection. It will then apply this knowledge to develop molecules that prevent these bacteria from obtaining iron, as a means of treating these diseases.
Healthy Lungs For Life: A Life Course Approach To Reduce COPD
Funder
National Health and Medical Research Council
Funding Amount
$2,491,398.00
Summary
Chronic Obstructive Lung Disease (COPD) causes breathing distress, disability and premature death. I have shown that COPD mostly has its origins in childhood. This means we can now identify early life risk factors to prevent COPD or help us catch it early, to improve health. My 5-year vision is to reduce the dire burden of COPD by creating evidence to change guidelines and policy and facilitating the transfer of that knowledge to practice.
Crosstalk Between The Repressive Histone Methyltransferases PRC2 And G9A: Structure-function Investigation To Open New Therapeutic Opportunities
Funder
National Health and Medical Research Council
Funding Amount
$595,205.00
Summary
The gene expression programs need to be precisely regulated and the misregulation of these programs can cause a broad range of human diseases. My research will focus on two protein complexes, which heavily contribute to the regulation of gene expression. My study will open a new path for developing new therapeutic strategies.
Reducing The Mortality Gap For People With Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$1,231,125.00
Summary
People with schizophrenia die >16 years earlier than the general population, mostly due to avoidable diseases such as diabetes and heart disease. This research aims to conduct clinical trials among people with schizophrenia of 1. an existing diabetes medication (metformin) to prevent initial weight gain due to antipsychotic medications and 2. a novel diabetes medication (exenatide) to help people who don’t have adequate weight loss with metformin.